2-chloro-N6-cyclopentyladenosine enhances the anticonvulsant action of carbamazepine in the mouse maximal electroshock-induced seizure model

Pharmacological Reports

Volumn 57, Issue 6, 2005, Pages 787-794

  Łuszczki, Jarogniew J ^a   Kozicka, Maria ^a   Świader, Mariusz J ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

2 chloro N6 cyclopentyladenosine; Adenosine A1 receptors; Antiepileptic drugs; Carbamazepine; Maximal electroshock

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; 8 CYCLOPENTYLTHEOPHYLLINE; ADENOSINE A1 RECEPTOR; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE; 2 CHLORO N(6)CYCLOPENTYLADENOSINE; 2-CHLORO-N(6)CYCLOPENTYLADENOSINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ELECTRIC SHOCK; LONG TERM MEMORY; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PHARMACODYNAMICS; SEIZURE; SEIZURE THRESHOLD; ANIMAL; BRAIN; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; METABOLISM;

ADENOSINE; ANIMALS; ANTICONVULSANTS; BRAIN; CARBAMAZEPINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTROSHOCK; MALE; MICE; RECEPTOR, ADENOSINE A1; SEIZURES; XANTHINES;

EID: 33645691425     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Adami M, Bertorelli R, Ferri N, Foddi MC, Ongini E: Effects of repeated administration of selective adenosine A1 and A2A receptor agonists on pentylenetetrazole-induced convulsions in the rat. Eur J Pharmacol, 1995, 294, 383-389.
2. Ault B, Wang CM: Adenosine inhibits epileptiform activity arising in hippocampal area CA3. Br J Pharmacol, 1986, 87, 695-703.
3. Boissier JR, Tardy J, Diverres JC: Une nouvelle methode simple pour explorer l'action «tranquilisante» le test de la cheminee. Med Exp (Basel), 1960, 3, 81-84.
4. Borowicz KK, Łuszczki J, Czuczwar SJ: 2-Chloroadenosine, a preferential agonist of adenosine A1 receptors, enhances the anticonvulsant activity of carbamazepine and clonazepam in mice. Eur Neuropsychopharmacol, 2002, 12, 173-179.
5. Bueters TJ, IJzerman AP, van Helden HP, Danhof M: Characterization of the pharmacokinetics, brain distribution, and therapeutic efficacy of the adenosine A1 receptor partial agonist 2'-deoxy-N6-cyclopentyladenosine in sarin-poisoned rats. Toxicol Appl Pharmacol, 2003, 192, 86-94.
6. 2+ levels in neuronal culture. Eur J Pharmacol, 1992, 219, 53-57.
7. Chapman AG, Croucher MJ, Meldrum BS: Anticonvulsant activity of intracerebroventricularly administered valproate and valproate analogues. A dose-dependent correlation with changes in brain aspartate and GABA levels in DBA/2 mice. Biochem Pharmacol, 1984, 33, 1459-1463.
8. Concas A, Santoro G, Mascia MP, Maciocco E, Dazzi L, Ongini E, Biggio G: Anticonvulsant doses of 2-chloro-N6-cyclopentyladenosine, an adenosine A1 receptor agonist, reduce GABAergic transmission in different areas of the mouse brain. J Pharmacol Exp Ther, 1993, 267, 844-851.
9. Corradetti R, Lo Conte G, Moroni F, Passani MB, Pepeu G: Adenosine decreases aspartate and glutamate release from rat hippocampal slices. Eur J Pharmacol, 1984, 104, 19-26.
10. Czuczwar SJ, Szczepanik B, Wamil A, Janusz W, Kleinrok Z: Differential effects of agents enhancing purinergic transmission upon the antielectroshock efficacy of carbamazepine, diphenylhydantoin, diazepam, phenobarbital, and valproate in mice. J Neural Transm Gen Sect, 1990, 81, 153-166.
11. De Sarro G, De Sarro A, Meldrum BS: Anticonvulsant action of 2-chloroadenosine injected focally into the inferior colliculus and substantia nigra. Eur J Pharmacol, 1991, 194, 145-152.
12. De Sarro G, Donato Di Paola E, Falconi U, Ferreri G, De Sarro A: Repeated treatment with adenosine A1 receptor agonist and antagonist modifies the anticonvulsant properties of CPPene. Eur J Pharmacol, 1996, 317, 239-245.
13. + pump. Adv Neurol, 1980, 27, 85-126.
14. DeLorenzo RJ, Sun DA: Phenytoin and other hydantoins. Mechanisms of action. In: Antiepileptic Drugs, 5th edn. Ed. Levy RH, Mattson RH, Meldrum BS, Perucca E, Lippincott Williams & Wilkins, Philadelphia, 2002, 551-565.
15. Dragunow M, Goddard GV, Laverty R: Is adenosine an endogenous anticonvulsant? Epilepsia, 1985, 26, 480-487.
16. Dunwiddie TV: The physiological role of adenosine in the central nervous system. Int Rev Neurobiol, 1985, 27, 63-139.
17. Dunwiddie TV, Masino SA: The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci, 2001, 24, 31-55.
18. Dunwiddie TV, Worth T: Sedative and anticonvulsant effects of adenosine analogs in mouse and rat. J Pharmacol Exp Ther, 1982, 220, 70-76.
19. Dunwiddie TV, Hoffer BJ, Fredholm BB: Alkylxanthines elevate hippocampal excitability. Evidence for a role of endogenous adenosine. Naunyn Schmiedebergs Arch Pharmacol, 1981, 316, 326-330.
20. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J: International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev, 2001, 53, 527-552.
21. Fujiwara Y, Sato M, Otsuki S: Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors. Psychopharmacology (Berl), 1986, 90, 332-335.
22. Gouder N, Fritschy JM, Boison D: Seizure suppression by adenosine A1 receptor activation in a mouse model of pharmacoresistant epilepsy. Epilepsia, 2003, 44, 877-885.
23. Hough CJ, Irwin RP, Gao XM, Rogawski MA, Chuang DM: Carbamazepine inhibition of N-methyl-D-aspartate-evoked calcium influx in rat cerebellar granule cells. J Pharmacol Exp Ther, 1996, 276, 143-149.
24. Huber A, Guttinger M, Mohler H, Boison D: Seizure suppression by adenosine A(2A) receptor activation in a rat model of audiogenic brainstem epilepsy. Neurosci Lett, 2002, 329, 289-292.
25. Kelly KM, Gross RA, Macdonald RL: Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett, 1990, 116, 233-238.
26. Khan GM, Smolders I, Ebinger G, Michotte Y: 2-Chloro-N(6)-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats. Neuropharmacology, 2001, 40, 657-667.
27. Lampe H, Bigalke H: Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport, 1990, 1, 26-28.
28. Larsson OM, Gram L, Schousboe I, Schousboe A: Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurones and astrocytes. Neuropharmacology, 1986, 25, 617-625.
29. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
30. Löscher W: Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs, 2002, 16, 669-694.
31. Luder AS, Parks JK, Frerman F, Parker WD Jr: Inactivation of beef brain alpha-ketoglutarate dehydrogenase complex by valproic acid and valproic acid metabolites. Possible mechanism of anticonvulsant and toxic actions. J Clin Invest, 1990, 86, 1574-1581.
32. Łuszczki JJ, Czuczwar SJ: Isobolographic and subthreshold methods in the detection of interactions between oxcarbazepine and conventional antiepileptics - a comparative study. Epilepsy Res, 2003, 56, 27-42.
33. Łuszczki JJ, Czuczwar SJ: Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn Schmiedebergs Arch Pharmacol, 2004, 369, 434-446.
34. Łuszczki JJ, Czuczwar SJ: Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. Eur Neuropsychopharmacol, 2005, 15, 133-142.
35. Łuszczki JJ, Świader M, Parada-Turska J, Czuczwar SJ: Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology, 2003, 28, 1817-1830.
36. Łuszczki JJ, Wójcik Ćwikła J, Andres MM, Czuczwar SJ: Pharmacological and behavioral characteristics of interactions between vigabatrin and conventional antiepileptic drugs in pentylenetetrazole-induced seizures in mice: an isobolographic analysis. Neuropsychopharmacology, 2005, 30, 958-973.
37. Macdonald RL: Carbamazepine. Mechanisms of action. In: Antiepileptic Drugs, 5th edn. Ed. Levy RH, Mattson RH, Meldrum BS, Perucca E, Lippincott Williams & Wilkins, Philadelphia, 2002, 227-235.
38. Macdonald RL, Kelly KM: Antiepileptic drug mechanisms of action. Epilepsia, 1995, 36, Suppl 2, S2-S12.
39. Macdonald RL, Rogers CJ, Twyman RE: Barbiturate regulation of kinetic properties of the GABAA receptor channel of mouse spinal neurones in culture. J Physiol, 1989, 417, 483-500.
40. Marangos PJ, Post RM, Patel J, Zander K, Parma A, Weiss S: Specific and potent interactions of carbamazepine with brain adenosine receptors. Eur J Pharmacol, 1983, 93, 175-182.
41. McLean MJ, Macdonald RL: Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther, 1986, 237, 1001-1011.
42. Murphy KM, Snyder SH: Heterogeneity of adenosine A1 receptor binding in brain tissue. Mol Pharmacol, 1982, 22, 250-257.
43. Nau H, Löscher W: Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and gamma-aminobutyric acid (GABA) metabolism in the mouse. J Pharmacol Exp Ther, 1982, 220, 654-659.
44. Parada-Turska J, Czuczwar M, Kiś J, Czuczwar P, Cioczek A, Łuszczki J, Czuczwar SJ: Allopurinol does not affect the anticonvulsant activity of carbamazepine and valproate in maximal electroshock-induced convulsions in mice. Pol J Pharmacol, 2004, 56, 67-72.
45. Phillips NI, Fowler LJ: The effects of sodium valproate on gamma-aminobutyrate metabolism and behavior in naive and ethanolamine-O-sulphate pretreated rats and mice. Biochem Pharmacol, 1982, 31, 2257-2261.
46. Phillis JW: Interactions of the anticonvulsants diphenyl-hydantoin and carbamazepine with adenosine on cerebral cortical neurons. Epilepsia, 1984, 25, 765-772.
47. 2+ uptake processes in guinea pig cerebral cortex synaptosomes. Can J Physiol Pharmacol, 1987, 65, 538-543.
48. Rho JM, Donevan SD, Rogawski MA: Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. J Physiol, 1996, 497(Pt 2), 509-522.
49. Rogawski MA, Porter RJ: Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev, 1990, 42, 223-286.
50. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB: Neuroprotective role of adenosine in cerebral ischaemia. Trends Pharmacol Sci, 1992, 13, 439-445.
51. Schumacher TB, Beck H, Steinhauser C, Schramm J, Elger CE: Effects of phenytoin, carbamazepine, and gabapentin on calcium channels in hippocampal granule cells from patients with temporal lobe epilepsy. Epilepsia, 1998, 39, 355-363.
52. Skerritt JH, Davies LP, Johnston GA: Interactions of the anticonvulsant carbamazepine with adenosine receptors. 1. Neurochemical studies. Epilepsia, 1983, 24, 634-642.
53. Stella L, Berrino L, Maione S, de Novellis V, Rossi F: Cardiovascular effects of adenosine and its analogs in anaesthetized rats. Life Sci, 1993, 53, 755-763.
54. 2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents. J Neurophysiol, 1998, 79, 240-252.
55. Van Calker D, Steber R, Klotz KN, Greil W: Carbamazepine distinguishes between adenosine receptors that mediate different second messenger responses. Eur J Pharmacol, 1991, 206, 285-290.
56. Venault P, Chapouthier G, de Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J: Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks. Nature, 1986, 321, 864-866.
57. Von Lubitz DK, Paul IA, Carter M, Jacobson KA: Effects of N6-cyclopentyl adenosine and 8-cyclopentyl-1,3-dipropylxanthine on N-methyl-D-aspartate induced seizures in mice. Eur J Pharmacol, 1993, 249, 265-270.
58. Weir RL, Padgett W, Daly JW, Anderson SM: Interaction of anticonvulsant drugs with adenosine receptors in the central nervous system. Epilepsia, 1984, 25, 492-498.
59. Zeise ML, Kasparow S, Zieglgansberger W: Valproate suppresses N-methyl-D-aspartate-evoked, transient depolarizations in the rat neocortex in vitro. Brain Res, 1991, 544, 345-348.